Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the furopyrimidine class. It is an experimental compound with no approved medical indications. The primary known mechanism of action is inhibition of serine/threonine-protein kinase Chk1 (checkpoint kinase 1), a key regulator in the DNA damage response pathway and cell cycle control. This compound has been studied as a potential checkpoint kinase inhibitor for research purposes but has not advanced into clinical development or approval for any disease. Its molecular formula is C22H21N3O4 and it is also referenced by code names such as AK-IN‑1 and DB08392.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[5,6-bis-(4-methoxy-phenyl)-furo[2,3-d]pyrimidin-4-ylamino]-ethanol.